American Oriental Bioengineering Reports Third Quarter 2010 Financial Results: EPS of $0.07

American Oriental Bioengineering, Inc. AOB, (the "Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced financial results for the third quarter ended September 30, 2010. Third Quarter 2010 Financial Performance In the third quarter of 2010, revenue continued its double-digit growth, increasing 16.1% year over year to $91.5 million from $78.8 million. The overall increase in sales was supported by the Company's continuous marketing efforts, new product offerings, as well as further expansion in the rural market. Net income attributable to controlling interest for the third quarter of 2010 was $5.3 million, or $0.07 per diluted share, compared to $10.0 million, or $0.13 per diluted share, in the prior year period.